Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Iowa State plant scientists tweak their biopharmaceutical corn research project

Iowa State plant scientists tweak their biopharmaceutical corn research project

June 26, 2006

AMES, Iowa — A biopharmaceutical corn created at Iowa State University is getting a makeover. Researchers are developing the corn into a variety that keeps the therapeutic protein, but eliminates the pollen. And they're using traditional breeding to do it.

ISU researchers have had promising results using the biopharmaceutical corn to treat bacterial diarrhea in pigs.




Now they are shifting their focus. They are developing a male sterile corn that carries the transgene. Because male sterile corn plants do not produce pollen, the new biopharmaceutical variety could be grown in corn-producing states without risk of pollinating traditional corn varieties.

"Pollen movement is the issue," said Kendall Lamkey, interim chair of agronomy and Pioneer Distinguished Chair in Maize Breeding. "And that's the most controllable part of the corn production system."

Lamkey, who also directs the Raymond F. Baker Center for Plant Breeding, leads the breeding portion of the research. Kan Wang, the principal researcher, who successfully transformed the corn, is professor of agronomy and director of the Center for Plant Transformation. Both centers are part of Iowa State's Plant Sciences Institute, which initiated the research. The ongoing project is supported by the institute and the College of Agriculture.

Lamkey and Wang say it will take about five growing seasons to make all the breeding crosses needed. The first season took place last winter in the Plant Sciences Institute's Roy J. Carver Co-Laboratory biosafe greenhouse. The biopharmaceutical corn was crossed with the non-transgenic, male-fertile corn line to produce a transgenic F1 hybrid.

Seeds from that cross are being used this summer in a field trial on remote land owned by Iowa State.

The breeding process in the field trial will not shed transgenic pollen. The transgenic crop will be detasseled. It will be surrounded by rows of non-transgenic corn, which will pollinate the detasseled transgenic plants.

Iowa State received permit approval from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) and from the state for the research.

The research plot is located on less than one-half acre of university land in Marshall county. It is about a half mile away from and was planted 28 days later than the nearest commercial corn. A fence will keep out wildlife. The research exceeds APHIS requirements for field trials of regulated plants.

The seed harvested in the fall will be used in the winter again in the high containment greenhouse. Another field trial is expected to take place next summer.

The 2006 field trial is the latest in a series of transgenic corn experiments led by Iowa State researchers. All have received federal and state approval. The trials have taken place three times in Iowa and once in Colorado.

The research is part of Iowa State's work to evaluate the safe use of plants for the production of proteins for pharmaceuticals and industrial products.

Wang engineered the corn to produce LT-B, a protein subunit produced by some strains of E. coli. Research has shown the ability of the protein to stimulate protective immune antibodies. Other Iowa State scientists have been evaluating grain from previous years' studies to understand how the corn-based pharmaceutical can help protect livestock from bacterial infections.

The system being developed in corn will work with other proteins. Corn is the preferred plant for producing proteins for non-food products.

"It's so easy to manipulate from a breeding perspective, and the pollen can be controlled," Lamkey said. "You can't control the pollen easily in self-pollinating crops like soybeans."

"And from a molecular biology and biochemistry point of view, we know so much about corn," Wang said. "Corn seed is such a good reservoir for foreign protein. And the grain, from a pharmacological standpoint, is the grain best tolerated by humans and animals both. Almost nobody is allergic to corn protein."

Lamkey said Iowa State is uniquely qualified to pursue this research because of access to germplasm and "not many places have the genetic transformation capabilities that Iowa State has."

Lamkey and Wang are considering breeding the transgene into a higher yielding, better seed producing, transformable corn inbred line.

"The line that has been used for this corn is really hard to work with in terms of pollination and seed production. It was bred for the purpose of transformation not the field," Lamkey said.

"The best part of this project is that finally conventional breeders like me are now working with molecular biologists like Dr. Wang," Lamkey said. "We're trying to get something that's mutually beneficial. This hasn't happened enough in the public sector."

Iowa State University



Related Biopharmaceutical Current Events and Biopharmaceutical News Articles Biopharmaceutical Current Events and Biopharmaceutical News RSS Biopharmaceutical Current Events and Biopharmaceutical News RSS
Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.

Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor
This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities.

Therapeutic nanoparticles give new meaning to sugar-coating medicine
A research team at the National Institute of Standards and Technology (NIST) studying sugar-coated nanoparticles for use as a possible cancer therapy has uncovered a delicate balancing act that makes the particles more effective than conventional thinking says they should be.

Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last time point assessed (13 hours) after administration.

Cottonseed-Based Drug Shows Promise Treating Severe Brain Cancer, Say UAB Researchers
An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer.

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

Drug shows activity in men with advanced prostate cancer
A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels - a marker for tumor growth - in men with advanced prostate cancer for whom traditional treatment options have failed.

Stem cell therapy grows new blood vessels
Research led by David Hess of the Robarts Research Institute at The University of Western Ontario has identified how to use selected stem cells from bone marrow to grow new blood vessels to treat diseases such as peripheral artery disease.

Breakthrough model for human cancer may improve development of cancer drugs; study in PNAS
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings from its novel human-in-mouse (HIM) cancer model system, in which AVEO successfully created invasive human tumors from primary human breast tissue that develop over time in mice and mimic human tumor behaviors and response.

Experimental Parkinson's therapy may have robust weight-loss effect
A growth factor used in clinical experiments to rescue dying brain cells in Parkinson patients may cause unwanted weight loss if delivered to specific areas of the brain, according to University of Florida researchers in the March online edition of Molecular Therapy.
More Biopharmaceutical Current Events and Biopharmaceutical News Articles
Biopharmaceuticals: Biochemistry and Biotechnology

Biopharmaceuticals: Biochemistry and Biotechnology
by Gary Walsh (Author)

The latest edition of this highly acclaimed textbook, provides a comprehensive and up-to-date overview of the science and medical applications of biopharmaceutical products. Biopharmaceuticals refers to pharmaceutical substances derived from biological sources, and increasingly, it is synonymous with 'newer' pharmaceutical substances derived from genetic engineering or hybridoma technology.

This superbly written review of the important areas of investigation in the field, covers drug production, plus the biochemical and molecular mechanisms of action together with the biotechnology of major biopharmaceutical types on the market or currently under development. There is also additional material reflecting both the technical advances in the area and detailed information on key topics...

  Biopharmaceuticals
by Landes Bioscience % Jesse



Quality by Design for Biopharmaceuticals: Principles and Case Studies (Wiley Series in Biotechnology and Bioengineering)

Quality by Design for Biopharmaceuticals: Principles and Case Studies (Wiley Series in Biotechnology and Bioengineering)
by Anurag S. Rathore (Editor), Rohin Mhatre (Editor)

The concepts, applications, and practical issues of Quality by Design

Quality by Design (QbD) is a new framework currently being implemented by the FDA, as well as EU and Japanese regulatory agencies, to ensure better understanding of the process so as to yield a consistent and high-quality pharmaceutical product. QbD breaks from past approaches in assuming that drug quality cannot be tested into products; rather, it must be built into every step of the product creation process.

Quality by Design: Perspectives and Case Studies presents the first systematic approach to QbD in the biotech industry. A comprehensive resource, it combines an in-depth explanation of basic concepts with real-life case studies that illustrate the practical aspects of QbD implementation....

Pall Solutions for the Biopharmaceutical Industry: Life Sciences

Pall Solutions for the Biopharmaceutical Industry: Life Sciences
by Pall



  European Biopharmaceutical Review
by Samedan Ltd

Provides information on the European Biopharmaceutical Sector. Includes interview feedback from industry leaders, company profiles, and articles on topics such as the European marketplace, public and business policy, biotech business strategy, science, innovation, and legal and regulatory issues.

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals

The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
by John Geigert (Author)

(Kluwer Academic) BioPharmaceutical Quality Solutions, Carlsbad, CA. Provides insight and practical suggesting in a common sense business approach for managing the Chemistry, Manufacturing & Controls (CMC) regulatory compliance requirements for biopharmaceuticals. Explains the biopharmaceutical CMC regulatory compliance, strategy development, and more.

Immunogenicity of Biopharmaceuticals (Biotechnology: Pharmaceutical Aspects)

Immunogenicity of Biopharmaceuticals (Biotechnology: Pharmaceutical Aspects)
by Marco van de Weert (Author), Marco van de Weert (Editor), Eva Horn Møller (Editor)

A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho s blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies.

This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune...

Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials

Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials
by Joy A. Cavagnaro (Editor)

"The goal is to provide a comprehensive reference book for the preclinicaldiscovery and development scientist whose responsibilities span target identification, lead candidate selection, pharmacokinetics, pharmacology, and toxicology, and for regulatory scientists whose responsibilities include the evaluation of novel therapies."
—From the Afterword by Anthony D. Dayan

Proper preclinical safety evaluation can improve the predictive value, lessen the time and cost of launching new biopharmaceuticals, and speed potentially lifesaving drugs to market. This guide covers topics ranging from lead candidate selection to establishing proof of concept and toxicity testing to the selection of the first human doses. With chapters contributed by experts in their specific...

Post-translational Modification of Protein Biopharmaceuticals

Post-translational Modification of Protein Biopharmaceuticals
by Gary Walsh (Editor)

From the leading author in the field, known around the world for his work and his authoritative publications, the contents of this book have been selected so as to reflect their relative importance for biopharmaceuticals. As a result, around half of the book is devoted to protein glycosylation, while the remainder is made up of other modifications, such as carboxylation, hydroxylation, sulfation, amidation and proteolytic processing. A final section addresses the latest trend of engineering the modification pattern to improve a given biopharmceutical, presenting several recent case studies of successful posttranslational engineering.
This first authoritative overview of the topic is an indispensable guide for drug developers and drug manufacturers with an interest in protein...

Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies (Biotechnology and Bioprocessing Series)

Process Validation in Manufacturing of Biopharmaceuticals: Guidelines, Current Practices, and Industrial Case Studies (Biotechnology and Bioprocessing Series)
by Anurag S. Rathore (Editor), Gail Sofer (Editor)

Written by top authorities in process validation, this reference explores current trends in the field and strategies for selecting the most appropriate quality control scheme. It offers practical guidelines, recommendations, and an abundance of case studies that showcase various techniques and approaches in the validation of biopharmaceutical processes. These include guidance on determining the life spans of chromatography and filtration media, process characterization and techniques for scaling-down unit operations in biopharmaceutical manufacturing, examples of contamination events, and practical methods for testing raw materials and in-process samples during various manufacturing stages.

© 2009 BrightSurf.com